Suppr超能文献

持续性阿片类药物使用者合并用药治疗慢性非恶性疼痛。

Concomitant medication among persistent opioid users with chronic non-malignant pain.

机构信息

Department of Circulation and Medical Imaging, Pain and Palliation Research Group, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.

出版信息

Acta Anaesthesiol Scand. 2012 Nov;56(10):1267-76. doi: 10.1111/j.1399-6576.2012.02766.x. Epub 2012 Sep 4.

Abstract

BACKGROUND

Recent guidelines for opioid treatment of chronic non-malignant pain discourage co-medication with benzodiazepines and benzodiazepine-related hypnotics, whereas co-medication with non-opioid analgesics and co-analgesics may offer a beneficial opioid sparing effect, and is recommended. The aim of this study was to describe 1-year periodic prevalence of co-medication with benzodiazepines, benzodiazepine-related hypnotics, non-opioid analgesics, co-analgesics and antidepressants in persistent opioid users with chronic non-malignant pain.

METHODS

The study is based on data from the Norwegian Prescription Database, covering all drugs dispensed to outpatients in 2008. Concomitant medication levels were compared between users in two definitions of persistent opioid use, all Norwegian adults dispensed opioids in 2008 and the Norwegian background population.

RESULTS

Of the Norwegian adult population studied, 1.2% met the criteria of persistent opioid use based on prescription pattern and prescription level. Sixty percent of persistent opioid users were dispensed a benzodiazepine or benzodiazepine-related hypnotic in amounts indicating regular use, with 15% dispensed a high amount of both classes. Sixty-two percent of persistent opioid users were dispensed one or more non-opioid analgesics, 47% an antidepressant and 33% were dispensed an antiepileptic drug.

CONCLUSION

Approximately 60% of persistent opioid users also receive benzodiazepines or benzodiazepine-related hypnotics in amounts indicating regular use. This is in conflict with recent guidelines for the treatment of chronic non-malignant pain and may indicate that these users are at an increased risk of developing problematic opioid use.

摘要

背景

最近关于慢性非恶性疼痛的阿片类药物治疗指南不鼓励合并使用苯二氮䓬类药物和苯二氮䓬类相关催眠药,而合并使用非阿片类镇痛药和辅助镇痛药可能具有有益的阿片类药物节约作用,因此被推荐。本研究的目的是描述慢性非恶性疼痛的持续性阿片类药物使用者中,1 年内合并使用苯二氮䓬类药物、苯二氮䓬类相关催眠药、非阿片类镇痛药、辅助镇痛药和抗抑郁药的周期性流行率。

方法

本研究基于 2008 年挪威处方数据库的数据,该数据库涵盖了所有向门诊患者发放的药物。在两种持续性阿片类药物使用定义中,比较了使用者的合并用药水平,这两种定义分别为 2008 年所有挪威成年人开出处方药和挪威背景人群。

结果

在所研究的挪威成年人群中,根据处方模式和处方水平,有 1.2%符合持续性阿片类药物使用的标准。60%的持续性阿片类药物使用者以表明常规使用的剂量开处了苯二氮䓬类药物或苯二氮䓬类相关催眠药,其中 15%开处了这两类药物的高剂量。62%的持续性阿片类药物使用者开了一种或多种非阿片类镇痛药,47%开了一种抗抑郁药,33%开了一种抗癫痫药。

结论

大约 60%的持续性阿片类药物使用者还以表明常规使用的剂量开处了苯二氮䓬类药物或苯二氮䓬类相关催眠药。这与最近关于慢性非恶性疼痛治疗的指南相冲突,可能表明这些使用者有发展为有问题的阿片类药物使用的风险增加。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验